SCHEMBL25801389

SCHEMBL25801389

CC(C)C(=O)CCc1ccc(O)c(CN(CCN(CC(=O)O)Cc2cc(CCC(=O)O)ccc2O)CC(=O)O)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.52
THRA P10827 3/20 0.40
THRB P10828 3/20 0.40
FFAR4 Q5NUL3 2/20 0.38
BACE1 P56817 1/20 0.37
POLB P06746 1/20 0.36
IAPP P10997 2/20 0.36
FFAR1 O14842 1/20 0.36
EGFR P00533 1/20 0.36
LCK P06239 1/20 0.36
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA12 O43570 1/20 0.36
CA9 Q16790 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CA4 P22748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1404313 0.91 FOLH1 (0.56) FOLH1FFAR4BACE1FFAR1EGFR
SCHEMBL18292001 0.89 FOLH1 (0.54) FOLH1THRATHRBFFAR4BACE1
SCHEMBL25741233 0.88 FOLH1 (0.52) FOLH1FFAR4BACE1POLBIAPP
SCHEMBL27303602 0.88 FOLH1 (0.52) FOLH1THRATHRBFFAR4BACE1
SCHEMBL22571849 0.86 FOLH1 (0.51) FOLH1THRATHRBFFAR4BACE1
SCHEMBL18811749 0.86 FOLH1 (0.58) FOLH1THRATHRBFFAR1CA1
SCHEMBL22131080 0.85 FOLH1 (0.52) FOLH1BACE1IAPP
SCHEMBL18811743 0.84 FOLH1 (0.56) FOLH1THRATHRBFFAR4CA1
SCHEMBL25797889 0.84 FOLH1 (0.49) FOLH1THRATHRBFFAR4BACE1
SCHEMBL29340370 0.84 FOLH1 (0.51) FOLH1FFAR4BACE1FFAR1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024057277-A1 DIAGNOSTIC PET IMAGING OF CARDIAC AMYLOIDOSIS Beijing Lado Technology Co., Ltd. (CN) 2024-03-21 WO disclosed
US-20230212549-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212549-A1 COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF FIBP, FN1, TPX2 FOLH1 1082/4885THRA 2231/4885THRB 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.